Today, On 17th October, The Supreme Court dismissed Roche’s appeal challenging the Delhi High Court’s refusal to restrain Natco Pharma from producing Risdiplam for Spinal Muscular Atrophy, observing it would not interfere since the High Court’s concurrent findings were interim in nature.
The Supreme Court asked a drug manufacturer if medicine for the rare disease Spinal Muscular Atrophy (SMA) can be made available at a lower price in India. The Court said that the Union of India and Seba PA can contact companies making the drug. This would help ensure affordable treatment for patients. The aim is to reduce the financial burden on families dealing with SMA.